Sponsor of the Day:
Jerkmate
https://www.baltimoresun.com/2026/04/24/fda-psychedelic-drugs-review-trump/
FDA plans fast review of 3 psychedelic drugs following Trump directive
fda plans fast3 psychedelic drugsfollowing trump directivereview
https://www.ocregister.com/2026/04/24/fda-psychedelic-drugs-review-trump/
FDA plans fast review of 3 psychedelic drugs following Trump directive
fda plans fast3 psychedelic drugsfollowing trump directivereview
https://www.ctvnews.ca:443/health/article/us-fda-plans-ultra-fast-review-of-three-psychedelic-drugs-following-trump-directive/
Trump psychedelics: U.S. FDA plans ultra-fast review of 3 drugs
Apr 24, 2026 - The U.S. Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions,...
fda plansultra fasttrumppsychedelicsreview
https://www.theepochtimes.com/us/fda-plans-quick-review-of-psychedelic-drugs-as-mental-health-treatments-6016820
FDA Plans Quick Review of Psychedelic Drugs as Mental Health Treatments | The Epoch Times
Apr 24, 2026 - Regulators did not identify the companies receiving vouchers.
mental health treatmentsfda plansquick reviewpsychedelic drugsepoch times
https://www.orlandosentinel.com/2026/04/24/fda-psychedelic-drugs-review-trump/
FDA plans fast review of 3 psychedelic drugs following Trump directive
fda plans fast3 psychedelic drugsfollowing trump directivereview
https://www.sun-sentinel.com/2026/04/24/fda-psychedelic-drugs-review-trump/
FDA plans fast review of 3 psychedelic drugs following Trump directive
fda plans fast3 psychedelic drugsfollowing trump directivereview
https://www.denverpost.com/2026/04/24/fda-psychedelic-drugs-review-trump/
FDA plans fast review of 3 psychedelic drugs following Trump directive
fda plans fast3 psychedelic drugsfollowing trump directivereview
https://www.kob.com/ap-top-news/fda-plans-ultra-fast-review-of-three-psychedelic-drugs-following-trump-directive/
FDA plans ultra-fast review of three psychedelic drugs following Trump directive - KOB.com
Apr 24, 2026 - The Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for hard-to-treat mental health conditions,...
psychedelic drugs followingfda plansultra fasttrump directivereview
https://www.theepochtimes.com/us/fda-plans-quick-review-of-psychedelic-drugs-as-mental-health-treatments-6016820?cmt=1
FDA Plans Quick Review of Psychedelic Drugs as Mental Health Treatments | The Epoch Times
Apr 26, 2026 - Regulators did not identify the companies receiving vouchers.
mental health treatmentsfda plansquick reviewpsychedelic drugsepoch times
https://www.dailypress.com/2026/04/24/fda-psychedelic-drugs-review-trump/
FDA plans fast review of 3 psychedelic drugs following Trump directive
fda plans fast3 psychedelic drugsfollowing trump directivereview
https://www.biospace.com/drug-development/sarepta-plans-fda-run-for-duchenne-exon-skippers-despite-confirmatory-trial-failure
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure - BioSpace
Mar 19, 2026 - Sarepta Therapeutics says the FDA has agreed to review a regulatory package for Amondys 45 and Vyondys 53 after they failed a confirmatory trial, but whether...
trial failuresareptaplansfdarun